The annual gathering, the world's largest biotech business event, draws more than 1,500 companies, investors and research bodies and over 20,000 participants.
Celltrion plans to use the convention less as a showcase than as a platform to firm up its growth strategy, leaning on the research, manufacturing and commercialization muscle it accumulated in biosimilars to chase deals in next-generation fields.
At its booth, Celltrion will present AI tools for discovering new targets, designing multispecific antibodies, assessing developability in silico and integrating research data through a platform it calls the Healthcare Intelligence Bank.
The systems predict an antibody candidate's properties, manufacturability and immunogenicity to weed out weak prospects early and shorten development timelines.
The firm will also spotlight its ADC and multispecific antibody pipelines, pitching the technologies to global pharmaceutical companies, biotech firms and investors while pursuing in-licensing, co-development and supply-chain meetings to sharpen its competitive edge.
"BIO is the largest global business stage where biotech companies, investors and technology partners from around the world come together," said a Celltrion spokesperson, adding that the event would help the company press its ambition to grow beyond biosimilars into a global drug developer.
Copyright ⓒ Aju Press All rights reserved.
